The purpose of this study was to explore clinical markers reflecting developmental changes in drug clearance by preterm infants.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Neonatal theophylline pharmacokinetics are influenced by developmental changes in liver metabolism and urinary elimination.
• Previous population pharmacokinetic studies have focused on the effect of weight and age.
• Previous studies have not explored the effects of phenotypic cytochrome P450 1A2 (CYP1A2) activity and genetic polymorphism on theophylline pharmacokinetics in preterm infants.
WHAT THIS STUDY ADDS
• CYP1A2 activity is a major determinant of theophylline clearance in preterm infants.
• Genetic polymorphisms do not affect CYP1A2 activity during the preterm and neonatal period.
• Noninvasive urinary metabolite analyses in real time can be used to assess developmental changes in theophylline clearance by preterm infants.
Introduction
The newborn population, especially preterm infants receiving intensive care, are the most vulnerable to the adverse effects of drugs because of their immaturity. Most drugs employed in the newborn population have been introduced without determining the appropriate dose, efficacy or safety because of the ethical concerns about clinical trials in these patients, the difficulties for frequent blood sampling, the limited number of patients available for study and the lack of appropriate study designs. Novel clinical trial designs are required in neonates to address these issues related to ethics, acceptability, rarity, standardization, end points, safety, dosing and feasibility [3] . These days, population pharmacokinetics [4] [5] [6] and metabolomics [7] [8] [9] have been introduced as new technologies in neonatal pharmaceutical clinical trials.
Methylxanthines have been commonly used as medications in preterm infants since the 1970s and their mechanism of action and metabolic pathway are relatively well established [10, 11] . The pharmacokinetics of theophylline (TP, 1,3-dimethylxanthine) in neonates differ from those observed in adults [12, 13] : (i) its oral bioavailability is about 80%; (ii) its protein binding is low in neonates; (iii) its serum half-life is prolonged from 20 to 30 hours; (iv) adult clearance values are reached at approximately 55 weeks postmenstrual age (PMA); and (v) 50% of the dose is excreted unchanged in the urine. The pharmacokinetics of TP in preterm infants are influenced by developmental changes in its metabolism by liver enzymes and urinary elimination [14, 15] ; clearance of TP seems to mature and change continuously as the PMA increases, but the pattern and timing of these changes remain controversial.
Cytochrome P450 1A2 (CYP1A2) [16] is one of the major hepatic enzymes in humans and it plays important roles in the metabolism of xenobiotics (e.g., clozapine, TP, tacrine and zolmitriptan) and in the metabolism of endogenous molecules (e.g., steroids, retinols, melatonin and arachidonic acids). The estimated contribution rate of CYP1A2 to TP metabolism is 90-95% in adults (Figure 1 ), and it is mainly involved in N-demethylation. Other minor hepatic enzymes that contribute to TP metabolism include CYP2E1 and CYP3A4, which are associated with 8-hydroxylation. The drug metabolic ability of individual patients can be assessed indirectly by measuring biomarkers that reflect CYP activity.
The technical difficulties and limited circulating blood volume in neonates, and especially in preterm infants, exclude standard pharmacokinetic and pharmacodynamic study designs with repeated sampling. Therefore, there have been several attempts to predict drug concentrations using noninvasive methods employing saliva [17] or urine [18] samples, and modelling [19] ; however, the optimal approach to this has not yet been established. To address this, we aimed to explore clinical markers reflecting the developmental change in TP pharmacokinetics in preterm infants using a noninvasive approach. This study evaluated the relationships between TP clearance (total, renal and nonrenal clearance) and clinical characteristics, including CYP1A2 activity, in preterm infants.
Methods

Subjects
Preterm infants younger than 37 weeks gestational age who had been admitted to the neonatal intensive care unit of Seoul National University (SNU) Children's Hospital, SNU Bundang Hospital and Seoul Metropolitan Government (SMG)-SNU Boramae Medical Center were enrolled in this study from July 2010 to December 2011. Preterm infants were included in the study if they were treated for apnoea of prematurity using intravenous (IV) aminophylline or peroral (PO) TP. The exclusion criteria were: (i) any major congenital anomaly; (ii) death within 72 h after birth; and (iii) proven secondary apnoea.
The study protocol was approved by the Institutional Review 
Figure 1
The theophylline metabolic pathway. Molar percentages of the metabolites analyzed in our preterm infant group are expressed in parentheses. CYP1A2 is a major hepatic enzyme involved in the decomposition of approximately 90-95% of theophylline in human adults. CYP1A2 mainly catalyzes the conversion of theophylline to 1-methylxanthine and 3-methylxanthine (N-demethylation), while CYP2E1 and CYP3A4 catalyze the conversion of theophylline to 1,3-dimethyluric acid (8-hydroxylation). 1-Methylxanthine is oxidized very rapidly to 1-methyluric acid by xanthine oxidase Study protocol for collecting serum and urine samples
Infants diagnosed with apnoea of prematurity were prescribed a maintenance dose of 1.5-3.0 mg kg À1 every 8 or 12 h after the administration of a loading dose of 8.0 mg kg
À1
IV aminophylline or PO TP. The salt factor of aminophylline (TP with ethylenediamine at a 2:1 ratio) is 0.8, and the bioavailability of oral TP is approximately 80% in neonates [12] . Therefore, the same dose was administered when changing from IV aminophylline to PO TP. We obtained a trough blood sample and a 2 h, 4 h or 6 h postadministration blood sample at steady state (at least 5 days after starting aminophylline or TP). These were used to determine plasma TP concentrations and CYP1A2 genotypes. The blood sample volume was minimized to 500 μl using BD Microtainer Tubes (BD, NJ, USA). The amount of urine in the bladder before drug administration was checked using a Vivid 7 Dimension device (GE Vingmed Ultrasound AS N-1390; GE, Horten, Norway) and emptied by gentle manual compression. Urine samples were collected with an adhesive urine bag directly after drug administration to determine the concentration of TP and its targeted metabolites. Serum TP concentrations were measured within 3 hours in the Department of Laboratory Medicine, and the Department of Clinical Pharmacology and Therapeutics of each hospital was consulted for therapeutic drug monitoring. Centrifuged plasma, haemocytes and urine samples were kept at À70°C for CYP1A2 genotyping and urine TP metabolite determination.
Measurement of TP and its metabolites
Serum concentrations of TP were measured using a fluorescence polarization immunoassay, the AxSYM Theophylline II assay (AxSYM; Abbott Laboratories, Diagnostic Division, Abbott Park, IL, USA), in SNU Children's Hospital and SMG-SNU Boramae Medical Center or using a chemiluminescent microparticle immunoassay, the ARCHITECT i Theophylline assay (ARCHITECT; Abbott Laboratories) in SNU Bundang Hospital. There is no significant difference between the TP concentrations measured by these two different analytical methods [20] . High-performance liquid chromatography (Agilent 1100 HPLC system; Agilent Technologies, CA, USA)-tandem mass spectrometry (API 4000LC/MS/MS system, AB Sciex, MA, USA) was used to quantify TP and its metabolites: 3-methylxanthine (3X), 1-methylxanthine (1X), 1-methyluric acid (1U), 1,3-dimethyluric acid (13U), caffeine (C, 1,3,7-trimethylxanthine) and 1,7-dimethyluric acid (17U). Protein was removed from the urine samples using methanol. Phenacetin was used as an internal standard for quantification of the above compounds and was separated on a Luna C18 column (100 × 2.0 mm, 5 μm; Phenomenex, Torrance, CA, USA). Validation of this analytical procedure for the determination of each compound was performed according to FDA guidance. The calibration curves were linear over the range of 5-1000 ng ml À1 for TP, C, 1X and 17U, and of 100-2000 ng ml À1 for 3X, 1U and 13U (R 2 < 0.990). The intra-and interday precisions of the urine quality control samples were <12.52% for each compound. The accuracies were within 86.03-111.4% for each compound.
Analysis of CYP1A2 genotypes
Genomic DNA was isolated and purified from the peripheral leucocytes of each subject using DNA extractor kits (QIAamp DNA blood mini kit; QIAGEN GmbH, Germany). CYP1A2*1C (À3860 G > A, rs2069514) and CYP1A2*1F (À163 C > A, rs762551) genotypes were detected by real-time polymerase chain reaction (PCR), which was performed by incubation for 10 min at 95°C, followed by 50 cycles of denaturation for 15 s at 92°C, annealing for 1 min at 60°C, and extension for 1 min at 60°C using TaqMan SNP Genotyping Assays (Applied Biosystems, CA, USA) methods. The obtained data were analyzed using a 7500 Real-Time PCR System (Applied Biosystems, CA, USA).
Calculation of TP clearance and CYP1A2 activity
The area under the serum concentration-time curve (AUC) during the dosing interval at steady state was calculated for TP using the trapezoidal rule. The amount of drug excreted in urine (Ae) was calculated by multiplying the TP concentration in urine, the urine volume per hour and the dosing interval. The clearances of TP were calculated using the equations below:
• Total clearance (CLt) = Dose / AUC: serum clearance • Renal clearance (CLr) = Ae / AUC: urinary excretion • Non-renal clearance (CLnr) = CLt -CLr: enzyme activity, etc.
CYP1A2 activity was calculated using the ratio of metabolites to TP. We assessed CYP1A2 activity as the ratio: (1U + 3X) / TP, using urinary metabolites of TP with reference to a previous study [21] .
Statistical analysis
Descriptive data are appropriately presented as numbers or as the arithmetic mean AE standard deviation (range, median). A linear mixed effects model was used to compare the concentrations of TP in serially collected urine samples in each subject. The urine concentrations were used as dependent variables in the model, the subject was used as a random effect and sampling points were used as a fixed effect. The association of serum and urine TP concentrations was assessed using simple linear regression analysis. The relationship between CYP1A2 activity, the clearance of TP and other clinical characteristics was performed by simple and multiple stepwise linear regression analyses. A P-value <0.05 was considered statistically significant, and statistical analyses were conducted by IBM SPSS Statistics 19.0 (IBM, Somers, NY, USA) and SAS 9.3 (SAS Institute Inc., Cary NC, USA).
Results
Study population
A total of 110 patients were enrolled and 169 samples were collected during this study. We analyzed a total of 152 samples from 104 preterm infants, after excluding six patients with inadequate urine collection. The basic demographic data and clinical characteristics at the point of sampling in the study group are shown in Table 1 .
TP concentrations in serum and urine
There were no significant differences in the TP concentrations detected in the urine samples collected serially from each subject (P = 0.983). We found a good association between serum trough concentrations and urine concentrations of TP (Figure 2) . Serum trough concentrations of TP were correlated with the concentration of TP in spot urine (R = 0.863, P < 0.001), the molar percentage of TP to all metabolites (R = 0.477, P < 0.001) and the excreted amount of TP adjusted by urine volume (R = 0.760, P < 0.001).
CYP1A2 activity
CYP1A2 activity was positively correlated with PMA, postnatal age (PNA), weight, height, body mass index, serum aspartate aminotransferase and alanine aminotransferase, but was inversely related to serum blood urea nitrogen, creatinine and albumin levels ( Table 2) . Multiple linear regression analysis (Table 3) found that PNA and PMA were factors affecting CYP1A2 activity. CYP1A2*1C and CYP1A2*1F genotypes did not affect CYP1A2 activity (Tables 2 and 3 ).
Clearance of TP
The total, renal and nonrenal clearances of TP in our preterm infants' group were 0.50 AE 0. 29 Table 1 ). The proportion of renal clearance was 32% and that of nonrenal clearance was 68%. Table 2 shows the associations between each subject factor and TP clearance. Multiple linear regression analysis adjusting for compounding factors (Table 3) found that the factors associated with total clearance of TP were CYP1A2 activity, PNA, weight, and 24-h urine output. Similarly, nonrenal clearance was determined by CYP1A2 activity, weight, PNA and urine caffeine/TP ratio. Renal clearance was associated with the serum blood urea nitrogen level, urine caffeine/TP ratio and PNA. Correlation between the serum and urine theophylline concentrations. There was a good correlation between the serum trough theophylline concentration and the theophylline concentration in spot urine. The association between serum and urine theophylline concentrations was assessed using simple linear regression analysis
Discussion
We explored clinical markers reflecting TP clearance in preterm infants, including CYP1A2 activity, by analyzing urine metabolites using noninvasive methods. To our knowledge, this is the first published study to investigate the relationship between phenotypic CYP1A2 activity and pharmacokinetic characteristics in preterm infants. This study shows that developmental changes in CYP1A2 activity and in TP clearance were affected by PNA, rather than PMA, and that CYP1A2 activity had a greater influence on TP clearance than urinary excretion did during the preterm period. Previous population BUN, blood urea nitrogen; Cr, creatinine; AST, aspartate aminotransferase; ALT, alanine aminotransferase Simple linear regression was used for data analysis. a CYP1A2 activity = ratio of (1-methyluric acid +3-methylxanthine) / theophylline Table 3 Factors affecting CYP1A2 activity and theophylline clearance PNA, postnatal age; PMA, postmenstrual age; UO, urine output; BUN, blood urea nitrogen; C/TP, caffeine/theophylline Multiple stepwise linear regression analysis was used for data analysis. a CYP1A2 activity = ratio of (1-methyluric acid + 3-methylxanthine ) / theophylline pharmacokinetics studies of TP in preterm infants reported the importance of body weight and age [22] [23] [24] , which was consistent with our results. However, we also found that CYP1A2 activity was a major determinant of TP clearance in preterm infants. Several studies have reported developmental changes in the pharmacokinetics of TP in preterm infants, but the pattern and timing of these have not been fully elucidated [14, 15, 25] . TP clearance and urine metabolite patterns reach adult values from the age of 3 months to 3 years, depending on the study. Many studies have emphasized that TP elimination occurs primarily by renal excretion of unchanged drug because the available CYP1A2 would be easily saturated in preterm infants, and that PMA rather than PNA should be used to assess maturity in infancy. However, the present study found that nonrenal clearance, representing CYP1A2 activity, predominated over renal clearance, and that PNA was more crucial than PMA in the maturation of this process. These differences could occur due to the investigation of study populations with relatively early PMA (25 +3 -37 +1 ) and may reflect the fact that CYP1A2 is highly inducible at both the mRNA and protein levels by a variety of chemicals, by smoking and by several dietary factors experienced after birth [16] . In addition, neither the CYP1A2*1C nor CYP1A2*1F genotype affected TP clearance or CYP1A2 activity; this contrasted with the results in adults, where the CYP1A2*1C and CYP1A2*1F genotypes were associated with low and high CYP1A2 inducibility, respectively [26, 27] . These data suggest that genetic polymorphism-associated differences might not yet be expressed in this study population, where developmental changes in the phenotype may be more crucial determinants of activity. However, the relatively low coefficient of determination (R 2 = 0.165, Table 3 ) for CYP1A2 activity, PNA and PMA suggests the possibility that other unknown factors affect CYP1A2 activity in preterm infants. Therefore, the ability to evaluate phenotypic CYP1A2 activity directly using noninvasive urine metabolite analyses is very useful. Urine is the most suitable biological sample for metabolite analysis even in very young preterm infants, because of the simple and noninvasive collection methods involved. In addition, modelling approaches can facilitate the application of data acquired from a small number of patients to the entire patient population. In our study, the urinary excretion rates of TP were constant over time. This reflected the special environmental and physiological characteristics of these neonates, who were provided continuous IV fluid infusion or regular and frequent milk feeding at 2-or 3-h intervals and who could not control voiding intentionally in the neonatal intensive care unit. In our study, the concentration of TP in spot urine as well as the molar percentage or excreted amount of TP showed a good correlation with the serum trough concentration of TP. The use of spot urine to analyze TP concentrations could provide a more convenient and useful method in view of the difficulties associated with 24-h urine collection in neonates.
Recently, caffeine has been replacing TP for the treatment of apnoea of prematurity because its wider therapeutic window and longer half-life means that it does not require routine therapeutic drug monitoring [10] . Although the clinical importance of TP in preterm infants is diminishing, it is still used now and importantly, extensive data relating to the perinatal and neonatal maturation of the relevant metabolic pathways have been gathered over the past 40 years [14, 15, 25] . Therefore, we chose TP as a model drug to explore noninvasive clinical urinary metabolite markers that reflect developmental changes in preterm infants. Besides TP [22] [23] [24] , other population pharmacokinetic studies of various drugs in preterm infants have reported developmental changes that were associated with body weight and age [28] [29] [30] [31] [32] [33] . In preterm and newborn infants, developmental metabolic state may affect drug metabolism directly and can be expressed as the phenotypic enzyme activity by analyzing urinary metabolites. Our study design using noninvasive urine metabolite analyses can also be applied to other drug studies in preterm infants.
In conclusion, we confirmed that there was a significant association between the CYP1A2 activity assessed using urinary metabolites and TP clearance in preterm infants. CYP1A2 activity increased with age in preterm infants, and was independent of the CYP1A2 genotype. CYP1A2 activity, which can be monitored in real time using random urine samples collected using noninvasive methods, can thus be used to assess developmental changes in TP pharmacokinetics in preterm infants. We expect that the approach used in this study will be applicable to studies of the pharmacokinetic characteristics of other drugs in preterm infants.
